GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma

The cure rate for metastatic osteosarcoma has not substantially improved over the past decades. Clinical trials of anti-HER2 trastuzumab or anti-GD2 dinutuximab for metastatic or refractory osteosarcoma were n...

Source: Journal of Hematology and Oncology - December 10, 2020 Category: Hematology Authors: Jeong A. Park and Nai-Kong V. Cheung Tags: Research Source Type: research